BRPI0508063A - processo para a manufatura de uma composição farmacêutica, nsaid, e, composição farmacêutica - Google Patents

processo para a manufatura de uma composição farmacêutica, nsaid, e, composição farmacêutica

Info

Publication number
BRPI0508063A
BRPI0508063A BRPI0508063-0A BRPI0508063A BRPI0508063A BR PI0508063 A BRPI0508063 A BR PI0508063A BR PI0508063 A BRPI0508063 A BR PI0508063A BR PI0508063 A BRPI0508063 A BR PI0508063A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
nsaid
manufacture
formulated
compositions
Prior art date
Application number
BRPI0508063-0A
Other languages
English (en)
Inventor
Poul Bertelsen
Original Assignee
Nycomed Danmark Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Danmark Aps filed Critical Nycomed Danmark Aps
Publication of BRPI0508063A publication Critical patent/BRPI0508063A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PROCESSO PARA A MANUFATURA DE UMA COMPOSIçãO FARMACêUTICA, NSAID, E, COMPOSIçãO FARMACêUTICA Foi verificado que composições farmacêuticas compreendendo drogas insolúveis em água podem ser manufaturadas e formuladas de um modo que a que seja assegurada a dissolução rápida do fluido gástrico. De modo vantajoso, o processo de manufatura provê uma estabilidade significativamente aperfeiçoada, deste modo resultando em composições que podem ter uma vida em prateleira mais longa do que as drogas convencionalmente formuladas e processadas.
BRPI0508063-0A 2004-06-29 2005-06-28 processo para a manufatura de uma composição farmacêutica, nsaid, e, composição farmacêutica BRPI0508063A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200401021 2004-06-29
PCT/DK2005/000435 WO2006000228A2 (en) 2004-06-29 2005-06-28 Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention

Publications (1)

Publication Number Publication Date
BRPI0508063A true BRPI0508063A (pt) 2007-07-17

Family

ID=34973654

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508063-0A BRPI0508063A (pt) 2004-06-29 2005-06-28 processo para a manufatura de uma composição farmacêutica, nsaid, e, composição farmacêutica

Country Status (23)

Country Link
US (2) US20070218128A1 (pt)
EP (1) EP1916994B1 (pt)
JP (2) JP5438898B2 (pt)
KR (1) KR100875299B1 (pt)
CN (2) CN1976678B (pt)
AU (1) AU2005256321B2 (pt)
BR (1) BRPI0508063A (pt)
CA (1) CA2572359C (pt)
EA (2) EA200971133A1 (pt)
ES (1) ES2450648T3 (pt)
GE (1) GEP20094671B (pt)
IL (1) IL180071A0 (pt)
MA (1) MA28754B1 (pt)
MX (1) MXPA06015131A (pt)
NO (1) NO20065763L (pt)
NZ (1) NZ552208A (pt)
PL (1) PL1916994T3 (pt)
SA (2) SA05260191B1 (pt)
TN (1) TNSN06434A1 (pt)
TW (1) TWI376242B (pt)
UA (1) UA93353C2 (pt)
WO (1) WO2006000228A2 (pt)
ZA (1) ZA200700531B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0508063A (pt) * 2004-06-29 2007-07-17 Nycomed Danmark Aps processo para a manufatura de uma composição farmacêutica, nsaid, e, composição farmacêutica
CA2697150A1 (en) * 2007-08-17 2009-02-26 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
BE1018279A3 (fr) * 2008-09-09 2010-08-03 Squarepoint Pointcarre Sprl Composition de nimesulide orodispersible.
JP2010083826A (ja) * 2008-10-01 2010-04-15 Nihon Generic Co Ltd オキシカム系化合物を含む固形製剤を製造する方法
US11135188B2 (en) * 2009-05-11 2021-10-05 Bayer Healthcare Llc Method and composition to improve absorption of therapeutic agents
CN101693030A (zh) * 2009-10-22 2010-04-14 哈尔滨健迪医药技术有限公司 一种用于外用止痛的药物组合物及其制备方法
RU2012122654A (ru) * 2009-11-05 2013-12-10 Алкем Лабораториз Лтд. Стабильная фармацевтическая инъекционная композиция ацеклофенака и способ ее получения
EP2394641A1 (en) 2010-05-30 2011-12-14 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of lornoxicam
US20130122098A1 (en) * 2011-11-14 2013-05-16 Bayer Healthcare Llc Method and composition to improve absorption of therapeutic agents
CN103565812A (zh) * 2012-08-06 2014-02-12 徐静 一种含氯诺昔康的口服速释止痛制剂的制备方法
KR101890649B1 (ko) * 2013-07-30 2018-09-28 라이온 가부시키가이샤 정제
NO2699580T3 (pt) 2014-01-24 2018-02-24
BE1021194B1 (nl) * 2014-07-07 2015-07-14 Nordic Specialty Pharma Bvba Paracetamol tabletten
EP3260114A1 (en) 2016-06-21 2017-12-27 Omya International AG Method for the production of a dosage form
EP3260115A1 (en) * 2016-06-21 2017-12-27 Omya International AG Method for the production of a dosage form
CN107929247A (zh) * 2016-10-13 2018-04-20 长春海悦药业股份有限公司 一种布洛肾素那敏片剂组合物及其制备方法
PT3758708T (pt) * 2018-03-01 2025-02-13 Astrazeneca Ab Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
EP4243781A1 (en) 2020-11-13 2023-09-20 Bayer HealthCare, LLC Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof
JP7565207B2 (ja) * 2020-12-16 2024-10-10 株式会社ファンケル カルノシン酸含有固体組成物及びカルノシン酸の溶出促進方法
CN115645363B (zh) * 2022-10-31 2025-06-10 浙江普利药业有限公司 一种布美他尼注射液及其制备方法
CN115569123B (zh) * 2022-12-08 2023-03-14 则正(济南)生物科技有限公司 一种富马酸伏诺拉生片剂及其制备方法
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性ｄｐｐ１阻害剤及びその用途
GR1010732B (el) * 2023-06-02 2024-07-25 Ιουλια Κλεωνος Τσετη Φαρμακευτικη συνθεση ιβουπροφαινης και παρακεταμολης για απο του στοματος χορηγηση
WO2025162472A1 (en) 2024-01-31 2025-08-07 Insmed Incorporated Linear dipeptidyl peptidase 1 inhibitors and uses thereof
CN118373833A (zh) * 2024-03-21 2024-07-23 浙江震元制药有限公司 一种氯诺昔康-扑热息痛共无定形钠盐及其制备方法和应用、消炎镇痛药物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1209667B (it) * 1985-11-12 1989-08-30 Zambon Spa Composizione effeverscente adattivita' analgesica.
JP2906528B2 (ja) * 1990-02-14 1999-06-21 大正製薬株式会社 吸収を促進した内服用固形製剤
US5370878A (en) * 1993-09-30 1994-12-06 Hallmark Pharmaceuticals, Inc. Method for preparing a direct compression granulated acetaminophen composition
DK1078628T3 (da) * 1994-07-08 2009-02-23 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
GB9603699D0 (en) * 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
US6974595B1 (en) * 1996-05-17 2005-12-13 Proethic Pharmaceuticals, Inc. Pharmaceutical compositions based on Diclofenae
KR20010023256A (ko) * 1997-08-27 2001-03-26 헥살 아게 용해도와 생체 이용성이 개선된 신규의 멜록시캄 의약조성물
AU9062998A (en) * 1997-09-11 1999-03-29 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids)
US6184220B1 (en) * 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
EA004032B1 (ru) * 1998-09-10 2003-12-25 Нюкомед Данмарк А/С Фармацевтические композиции лекарственных веществ с быстрым высвобождением
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
YU57801A (sh) * 1999-12-08 2005-07-19 Pharmacia Corporation Polimorfni kristalni oblici celecoxib-a
US20030124176A1 (en) * 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
JP2005519865A (ja) * 2001-09-25 2005-07-07 ランバクシー ラボラトリーズ リミテッド 急速溶解性投薬形態物の製造方法
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
RS20050390A (sr) * 2002-11-26 2008-04-04 Boehringer Ingelheim Pharma Gmbh. & Co.Kg., Farmaceutska kompozicija koja obuhvata ltb4 antagonist i koks-2 inhibitor ili kombinovani koks1/2 inhibitor
WO2004071490A1 (en) * 2003-02-12 2004-08-26 R & P Korea Co., Ltd. Solvent system of hardly soluble drug with improved elution rate
US20040220264A1 (en) * 2003-03-17 2004-11-04 Yu Ruey J Bioavailability and improved delivery of acidic pharmaceutical drugs
BRPI0508063A (pt) * 2004-06-29 2007-07-17 Nycomed Danmark Aps processo para a manufatura de uma composição farmacêutica, nsaid, e, composição farmacêutica

Also Published As

Publication number Publication date
ZA200700531B (en) 2009-09-30
GEP20094671B (en) 2009-04-27
KR20070032035A (ko) 2007-03-20
SA05260191B1 (ar) 2009-09-02
NO20065763L (no) 2007-01-29
KR100875299B1 (ko) 2008-12-23
EP1916994B1 (en) 2013-12-11
TWI376242B (en) 2012-11-11
MXPA06015131A (es) 2007-03-26
CA2572359C (en) 2010-08-03
EA200971133A1 (ru) 2010-10-29
WO2006000228A3 (en) 2006-08-31
CN1976678A (zh) 2007-06-06
EA014443B1 (ru) 2010-12-30
IL180071A0 (en) 2007-05-15
EP1916994A2 (en) 2008-05-07
TNSN06434A1 (en) 2008-02-22
PL1916994T3 (pl) 2014-05-30
CN101513391B (zh) 2013-03-13
JP2008504307A (ja) 2008-02-14
CN101513391A (zh) 2009-08-26
US20070218128A1 (en) 2007-09-20
WO2006000228A2 (en) 2006-01-05
UA93353C2 (ru) 2011-02-10
ES2450648T3 (es) 2014-03-25
CA2572359A1 (en) 2006-01-05
US20130059842A1 (en) 2013-03-07
MA28754B1 (fr) 2007-07-02
JP5438898B2 (ja) 2014-03-12
AU2005256321A1 (en) 2006-01-05
CN1976678B (zh) 2010-06-02
SA108290833B1 (ar) 2012-03-24
AU2005256321B2 (en) 2008-11-20
EA200700078A1 (ru) 2007-06-29
WO2006000228B1 (en) 2006-11-09
NZ552208A (en) 2008-11-28
JP2011213730A (ja) 2011-10-27
TW200605919A (en) 2006-02-16

Similar Documents

Publication Publication Date Title
UA93353C2 (ru) Производство фармацевтических композиций c быстрым высвобождением ha ochobe водонерастворимых лекарсвенных средств и фармацевтические композиции, полученные способом согласно изобретению
ATE534383T1 (de) Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid
CY1116548T1 (el) Χρηση παραγωγων 1,3-διφαινυλπροπ-2-εν-1-ονης για την αγωγη ηπατικων διαταραχων
BRPI0608402B8 (pt) compostos de flavonóide e composições compreendendo os mesmos
TR200801336T1 (tr) Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
PA8784701A1 (es) Proceso y dispersión sólida que contiene revaprazan para la preparación del mismo
ECSP088758A (es) Métodos para reducir la aglomeración de proteína
NO20083780L (no) Topisk sammensetning omfattende en antibakteriell substans
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
BR112015000203A2 (pt) formulações de etanercept que exibem redução marcada em partículas sub-visíveis
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
HK1246173A1 (zh) 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
BRPI0707488B8 (pt) método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável
WO2007101710A8 (en) Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
AR053552A1 (es) Formas farmaceuticas con propiedades farmacocineticas mejoradas
AU2017262586A1 (en) Improved drug formulations
BRPI0704496A (pt) pigmentos de óxido férrico estáveis à oxidação, processo para a fabricação de pigmentos de óxido férrico, uso dos pigmentos de óxido férrico
NI201100119A (es) Composición de liberación pulsatil de sildenafil y proceso para prepararla.
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
EP4201941A4 (en) PYRAZOLE BORONIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND RELATED USES
NO20070187L (no) Oralt desintegrerende farmasoytisk preparat omfattende risperidon
MA29922B1 (fr) NOUVEAUX DERIVES DE BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE CMet
AR059452A1 (es) Un solvente no ionico , una composicion farmaceutica estabilizada que comprende un taxano y un proceso para la preparacion del solvente no ionico
TR200604349A2 (tr) Aripiprazol içeren farmasötik bileşimler
GT200400134A (es) Sistemas emulsionantes que contienen derivados de azetidina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2312 DE 28-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.